Comparative Pharmacology
Head-to-head clinical analysis: PEN VEE K versus PENICILLIN G PROCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEN VEE K versus PENICILLIN G PROCAINE.
PEN-VEE K vs PENICILLIN G PROCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg orally every 6-8 hours for mild to moderate infections; up to 2 g/day for severe infections.
1.2 million to 2.4 million units intramuscularly once daily for most infections (e.g., uncomplicated pneumonia); for neurosyphilis, 2.4 million units intramuscularly once daily plus probenecid 500 mg orally four times daily for 10-14 days. Administer deep IM injection, not IV.
None Documented
None Documented
Terminal elimination half-life: 30-60 minutes in adults with normal renal function, prolonged to 3-10 hours in severe renal impairment.
Terminal elimination half-life is approximately 0.5-1 hour in patients with normal renal function. Clinically, the prolonged absorption from the intramuscular depot results in sustained serum concentrations, with effective levels lasting 12-24 hours.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 60-90% of elimination; biliary/fecal elimination is minimal (<10%).
Primarily renal excretion via tubular secretion and glomerular filtration. Approximately 60-90% of a dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination is minor (<10%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic